drugset / Trial / NCT01701219

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NCT01701219

Phase 4 Completed 56 enrolled Forest Laboratories
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of vancomycin and/or daptomycin treatment.

Timeline

Start
2013-01
Primary completion
2014-05
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftaroline fosamil Other / unclassified 600 mg Intravenous